Working with its clients to ensure a successful outcome in terms of market access, Grove consultants based in Slovakia provide expert advice in three key areas:
Under the control of the Ministry of Health, and also under continual review, healthcare in Slovakia is universally available within the context of a system of compulsory health insurance, a basic benefit package, a competitive insurance package and flexible pricing of health services.
The system remains relatively inefficient and quality levels are low.
With EU membership has come a more transparent pricing structure and Slovakian legislation delineates clear rules and timelines for price approval and reimbursement of drugs. Alongside this, over the past ten years the Ministry of Health has pushed cost-containment heavily within the reimbursement policy in Slovakia. While stricter rules for price referencing and the introduction of a new set of regulations for the setting of reimbursements has led to visible cost savings, an increase in parallel exports and drop in local availability of the drugs in question. The re-export of pharmaceuticals has been banned as a consequence.
As in other areas, the State Institute for Drug Control (SUKL) plays the key role in pricing and reimbursement in the market for pharmaceuticals, medical devices, food supplements and cosmetics.
The Slovakian regulatory environment requires careful navigation. Only with an understanding of local pricing and reimbursement policies, can new market entrants hope to get their own price and reimbursement strategies and subsequent pricing and reimbursement submissions right. With experienced local consultants, Grove can assist with: